Health Care & Life Sciences » Biotechnology | Celldex Therapeutics Inc.

Celldex Therapeutics Inc. | Ownership

Companies that own Celldex Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
KLP Enterprises LLC
6,865,006
4.23%
0
100%
06/30/2018
Meditor Capital Management Ltd.
6,312,700
3.89%
0
0.6%
06/30/2018
The Vanguard Group, Inc.
5,595,121
3.44%
-284,998
0%
06/30/2018
Dimensional Fund Advisors LP
4,281,328
2.64%
113,743
0%
06/30/2018
Renaissance Technologies LLC
4,220,687
2.6%
4,066,273
0%
06/30/2018
BlackRock Fund Advisors
3,471,618
2.14%
-5,741,088
0%
06/30/2018
DWS Investment GmbH
2,603,221
1.6%
1,957,710
0%
06/30/2018
Millennium Management LLC
2,177,950
1.34%
273,066
0%
06/30/2018
Goldman Sachs & Co. LLC (Private Banking)
1,945,272
1.2%
1,497,976
0%
06/30/2018
PZU Asset Management SA
1,509,300
0.93%
59,300
0.08%
06/30/2017

About Celldex Therapeutics

View Profile
Address
Perryville III Building
Hampton New Jersey 08827
United States
Employees -
Website http://www.celldex.com
Updated 09/14/2018
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.